KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
about
Observational studies on evaluating the safety and adverse effects of traditional chinese medicineDifferent carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan.A fatal case of primary basaloid squamous cell carcinoma in the intrahepatic bile ducts.Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis.GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile ductMolecular diagnosis of intrahepatic cholangiocarcinoma.Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivoMolecular genetics and targeted therapeutics in biliary tract carcinoma.Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in miceReport of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence.Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.Histological Characterization of Biliary Intraepithelial Neoplasia with respect to Pancreatic Intraepithelial Neoplasia.Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.Molecular mechanism of cholangiocarcinoma carcinogenesis.Latest advances in the pathological understanding of cholangiocarcinomas.New Horizons for Precision Medicine in Biliary Tract Cancers.Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.New concept: cellular senescence in pathophysiology of cholangiocarcinoma.Cholangiocarcinoma with intraductal tubular growth pattern versus intraductal papillary growth pattern.MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma.Histological features of precancerous and early cancerous lesions of biliary tract carcinoma.Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis.Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report.Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification.Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens.The curious case of Gαs gain-of-function in neoplasia.EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs.Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
P2860
Q27024826-A5F7C245-5383-4FFB-AC16-90403B8E1990Q34121347-A04895FE-653D-477B-B41F-538CA27472C1Q34454193-69D9352B-2AC9-4C4D-9F4C-FF561E76E4B5Q34547888-FDBA8FDE-C2B6-4EF3-9B35-5DE06157AFEBQ35061297-6EE07C47-95A7-421B-AAD6-B6F7A8A5D8B6Q35592221-24453E0C-DFB5-4CDC-8358-A75563694D01Q36414323-576BDED6-4DF0-454B-8AFC-9EDD549BA49FQ36488070-01B4214D-2010-42DA-A184-9289B049C599Q36501683-F4AD419C-D83C-4B21-9070-EADF13270159Q37364842-67145F6B-4157-4098-90AB-F268FF6F1EC1Q37588461-460CE14F-1D8E-4916-A84E-C7161326BC77Q37730684-BBC09F26-363B-4932-BEDB-89FFDFC17A86Q38101517-D83EA89C-4B54-43A8-ACBF-EAFE09F575A9Q38217475-DA3D3BD0-A470-4C54-9B55-2A7FCFC627E9Q38613933-7EB0EC43-0839-4619-A758-E254CAFC7DEAQ38619219-8B53FEC5-B64C-433A-8B07-309E2FEC0D84Q38662233-948D0D94-9F67-4336-BD3A-E6F7FD9BEEF6Q38672946-D46CAE0D-0C5F-458F-A736-19B3E04198A6Q38920606-EB1DE399-D59A-419D-970D-429FB6DACBACQ38965092-0767FB41-FAC1-4790-A868-C79770DA7846Q40914280-ADF145CD-97B6-49CC-8FE9-6CA7D42B7D38Q42242186-075E42E3-25C4-415A-9EB3-6F5C5126FAADQ43058864-91A367E3-2009-424B-925B-83B917155D91Q47550861-7B037DCC-E76F-4BAF-B85F-F31F8D604807Q48000860-CC22DC56-586B-4DCE-A771-502D567784EDQ49487531-DC7424E1-5CE7-482C-8B14-1DB95A792EEAQ49927901-B295AB2A-05B9-4444-AB9B-3F20484A1DB1Q50694709-8E3F2AE5-4E26-463C-A8ED-DC1DFCE51BBAQ51687417-60675D60-E93E-462F-8369-58C1B39C7DB8Q53669411-BEF0674D-294A-40C7-B4E5-F746BF0C64F8Q54955004-70B2E72D-07B5-456E-9D0D-714BDA5A12A6Q55381085-3CF3748A-A6B5-44F8-B8FD-726B753C8DD8Q55662464-1561B1C4-F7FB-413F-B435-16229EF027A8Q57091632-FB67A886-1EBC-40AE-9264-76A0489C2BD4
P2860
KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@ast
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@en
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@nl
type
label
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@ast
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@en
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@nl
prefLabel
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@ast
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@en
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@nl
P2093
P356
P1433
P1476
KRAS and GNAS mutations and p5 ...... rahepatic cholangiocarcinomas.
@en
P2093
Maylee Hsu
Motoko Sasaki
Saya Igarashi
Yasuni Nakanuma
Yasunori Sato
P304
P356
10.1002/CNCR.27955
P407
P577
2013-01-18T00:00:00Z